IDEAYA Biosciences (IDYA) Earnings Date & Reports

Key Takeaways

• IDEAYA Biosciences reported a third quarter 2026 net loss of $125.7 million, or $1.22 per share, widening from a net loss of $112.5 million in the second quarter of 2026.
• Collaboration revenue rose to $10.2 million, up from $8.9 million in the prior quarter, exceeding the consensus estimate of roughly $7.6 million.
• The loss per share of $1.22 came in slightly below the consensus estimate of approximately $1.16, while revenue beat expectations.
• Research and development (R&D) expenses climbed to $121.6 million, reflecting the company's advancing clinical pipeline.
• IDEAYA completed its first NDA (New Drug Application) filing for darovasertib in metastatic uveal melanoma, a key commercial milestone.
• The company held approximately $1.15 billion in cash, cash equivalents, and marketable securities, with its cash runway guidance into 2030 unchanged.
• For more context on this ticker, explore the company's Major News, Today's Price Move, Price Targets, and Forecast pages.
• Interested in AI-driven trading ideas? Explore Trending AI Robots.

Earnings Context and Why It Matters

As a clinical-stage precision medicine oncology company, IDEAYA Biosciences does not yet generate product sales, so its quarterly results are shaped less by traditional revenue than by pipeline execution, partnership economics, and disciplined cash management. The third quarter of 2026 is notable because it included the company's first NDA filing for darovasertib, its lead program in metastatic uveal melanoma, a rare eye cancer. Investors are watching whether the company can convert clinical data into regulatory progress while keeping spending on track. A widening net loss driven by rising R&D and general and administrative (G&A) costs is expected for a company advancing multiple programs, making the cash runway and near-term clinical catalysts the true focal points of this report.

Reported Results

For the third quarter ended September 30, 2026, IDEAYA reported collaboration revenue of $10.2 million, up from $8.9 million in the second quarter of 2026, and above the consensus estimate of roughly $7.6 million. Revenue is recognized over time under the Servier exclusive license agreement for darovasertib, tied to research and development services.

Net loss for the quarter was $125.7 million, or $1.22 per share, compared with a net loss of $112.5 million in the prior quarter. The per-share loss of $1.22 came in modestly below the consensus estimate of approximately $1.16. R&D expenses rose to $121.6 million from $108.7 million sequentially, while G&A expenses increased to $26.3 million from $22.5 million.

The company ended the quarter with approximately $1.15 billion in cash, cash equivalents, and marketable securities, down from $1.24 billion as of June 30, 2026, driven primarily by cash used in operations. Management reiterated that its cash runway extends into 2030 under the current operating plan.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring companies like IDEAYA Biosciences, it offers a streamlined way to surface actionable setups across the biotech sector and beyond.

Market Reaction and Investor Sentiment

IDEAYA shares have declined roughly 8% since the start of 2026, underperforming the broader market, even as the company advanced its pipeline and completed its first NDA filing. The third quarter results highlighted a familiar dynamic for biotech investors: the earnings miss versus consensus was driven by rising clinical spending, while the revenue beat and the darovasertib regulatory milestone anchored the longer-term thesis. Sentiment around the stock remains tied to the company's ability to execute on clinical and regulatory catalysts rather than near-term profitability. With a consensus price target well above recent trading levels, analyst expectations remain constructive, but investors are closely watching whether upcoming data readouts support that view.

Forward Outlook and Key Factors to Monitor

Looking ahead, IDEAYA's story centers on a series of defined catalysts rather than quarterly earnings. The darovasertib NDA in metastatic uveal melanoma is the flagship near-term milestone, and investors will monitor regulatory interactions and any updates on potential approval timing.

On the clinical side, the company plans to host an R&D Day on November 16, 2026, where it will present new preclinical data on its MTAP/CDKN2A franchise in RAS-mutant cancers. This event is expected to provide scientific rationale for the clinical collaborations IDEAYA recently established with Roche and Genentech.

Several additional programs are advancing, including IDE849, a DLL3-directed TOP1i antibody-drug conjugate (ADC), in small-cell lung cancer and neuroendocrine tumors, as well as IDE892 and IDE397 in MTAP-deleted cancers. Investors should also watch expense trends, as R&D costs are likely to remain elevated with multiple trials enrolling simultaneously.

With approximately $1.15 billion in cash and a runway into 2030, IDEAYA has meaningful financial flexibility to fund its pipeline. The key question is whether the company can translate its expanding clinical portfolio into regulatory and commercial progress over the next several quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations